Angiogenesis in b cell lymphoproliferative diseases. Biological and clinical studies

Angelo Vacca, Domenico Ribatti, Luisa Roncali, Franco Dammacco

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammopathies of undetermined significance (MGUS), Microvessel density increased in parallel with the labeling index (LI%mdash;an indicator of plasma cell proliferating activity that correlates with prognosis-and defined a risk of MM progression in much the same way as LI% itself. Consequently, bone marrow angiogenesis could be an indication for unfavourable prognosis in MGUS and MM. Angiogenesis has also been demonstrated in lymph nodes involved by B cell non Hodgkin's lymphoma (B-NHL) belonging to the Working Formulation intermediate-grade (diffuse subtypes), and high-grade categories, but not in the low-grade and intermediate-grade (follicular subtype) categories. It correlated with the B-NHL cell proliferating activity, since large increments in this activity have already been demonstrated in intermediate-and high-grade vs low-grade tumors. Active MM, intermediate-grade, diffuse subtypes, and high-grade B-NHLs correspond to the vascular phases of B cell lymphoproliferative diseases, and could thus be assimilated to locally invasive and metastatic solid tumors. Similarly to solid tumors during these stages of progression, tumor B cells are also capable of inducing angiogenesis, both directly and indirectly by activating the inflammation infiltrate-a possibility that was first demonstrated by means of B-NHL implants onto the chick embryo chorioallantoic membrane. Anti-angiogenic therapy can be envisaged as a possible future development.

Original languageEnglish
Pages (from-to)27-38
Number of pages12
JournalLeukemia and Lymphoma
Volume20
Issue number1-2
DOIs
Publication statusPublished - 1995

Fingerprint

Multiple Myeloma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Monoclonal Gammopathy of Undetermined Significance
Neoplasms
B-Lymphocytes
Bone Marrow
Chorioallantoic Membrane
Chick Embryo
Microvessels
Plasma Cells
Blood Vessels
Lymph Nodes
Clinical Studies
Neoplasm Metastasis
Inflammation
Growth
Therapeutics

Keywords

  • Angiogenesis
  • Multiple myeloma
  • Non-Hodgkin's lymphoma
  • S-phase cells
  • Tumor progression

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Angiogenesis in b cell lymphoproliferative diseases. Biological and clinical studies. / Vacca, Angelo; Ribatti, Domenico; Roncali, Luisa; Dammacco, Franco.

In: Leukemia and Lymphoma, Vol. 20, No. 1-2, 1995, p. 27-38.

Research output: Contribution to journalArticle

Vacca, Angelo ; Ribatti, Domenico ; Roncali, Luisa ; Dammacco, Franco. / Angiogenesis in b cell lymphoproliferative diseases. Biological and clinical studies. In: Leukemia and Lymphoma. 1995 ; Vol. 20, No. 1-2. pp. 27-38.
@article{1e3887b5559e42bf8872dd89fb1faabf,
title = "Angiogenesis in b cell lymphoproliferative diseases. Biological and clinical studies",
abstract = "Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammopathies of undetermined significance (MGUS), Microvessel density increased in parallel with the labeling index (LI{\%}mdash;an indicator of plasma cell proliferating activity that correlates with prognosis-and defined a risk of MM progression in much the same way as LI{\%} itself. Consequently, bone marrow angiogenesis could be an indication for unfavourable prognosis in MGUS and MM. Angiogenesis has also been demonstrated in lymph nodes involved by B cell non Hodgkin's lymphoma (B-NHL) belonging to the Working Formulation intermediate-grade (diffuse subtypes), and high-grade categories, but not in the low-grade and intermediate-grade (follicular subtype) categories. It correlated with the B-NHL cell proliferating activity, since large increments in this activity have already been demonstrated in intermediate-and high-grade vs low-grade tumors. Active MM, intermediate-grade, diffuse subtypes, and high-grade B-NHLs correspond to the vascular phases of B cell lymphoproliferative diseases, and could thus be assimilated to locally invasive and metastatic solid tumors. Similarly to solid tumors during these stages of progression, tumor B cells are also capable of inducing angiogenesis, both directly and indirectly by activating the inflammation infiltrate-a possibility that was first demonstrated by means of B-NHL implants onto the chick embryo chorioallantoic membrane. Anti-angiogenic therapy can be envisaged as a possible future development.",
keywords = "Angiogenesis, Multiple myeloma, Non-Hodgkin's lymphoma, S-phase cells, Tumor progression",
author = "Angelo Vacca and Domenico Ribatti and Luisa Roncali and Franco Dammacco",
year = "1995",
doi = "10.3109/10428199509054750",
language = "English",
volume = "20",
pages = "27--38",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1-2",

}

TY - JOUR

T1 - Angiogenesis in b cell lymphoproliferative diseases. Biological and clinical studies

AU - Vacca, Angelo

AU - Ribatti, Domenico

AU - Roncali, Luisa

AU - Dammacco, Franco

PY - 1995

Y1 - 1995

N2 - Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammopathies of undetermined significance (MGUS), Microvessel density increased in parallel with the labeling index (LI%mdash;an indicator of plasma cell proliferating activity that correlates with prognosis-and defined a risk of MM progression in much the same way as LI% itself. Consequently, bone marrow angiogenesis could be an indication for unfavourable prognosis in MGUS and MM. Angiogenesis has also been demonstrated in lymph nodes involved by B cell non Hodgkin's lymphoma (B-NHL) belonging to the Working Formulation intermediate-grade (diffuse subtypes), and high-grade categories, but not in the low-grade and intermediate-grade (follicular subtype) categories. It correlated with the B-NHL cell proliferating activity, since large increments in this activity have already been demonstrated in intermediate-and high-grade vs low-grade tumors. Active MM, intermediate-grade, diffuse subtypes, and high-grade B-NHLs correspond to the vascular phases of B cell lymphoproliferative diseases, and could thus be assimilated to locally invasive and metastatic solid tumors. Similarly to solid tumors during these stages of progression, tumor B cells are also capable of inducing angiogenesis, both directly and indirectly by activating the inflammation infiltrate-a possibility that was first demonstrated by means of B-NHL implants onto the chick embryo chorioallantoic membrane. Anti-angiogenic therapy can be envisaged as a possible future development.

AB - Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammopathies of undetermined significance (MGUS), Microvessel density increased in parallel with the labeling index (LI%mdash;an indicator of plasma cell proliferating activity that correlates with prognosis-and defined a risk of MM progression in much the same way as LI% itself. Consequently, bone marrow angiogenesis could be an indication for unfavourable prognosis in MGUS and MM. Angiogenesis has also been demonstrated in lymph nodes involved by B cell non Hodgkin's lymphoma (B-NHL) belonging to the Working Formulation intermediate-grade (diffuse subtypes), and high-grade categories, but not in the low-grade and intermediate-grade (follicular subtype) categories. It correlated with the B-NHL cell proliferating activity, since large increments in this activity have already been demonstrated in intermediate-and high-grade vs low-grade tumors. Active MM, intermediate-grade, diffuse subtypes, and high-grade B-NHLs correspond to the vascular phases of B cell lymphoproliferative diseases, and could thus be assimilated to locally invasive and metastatic solid tumors. Similarly to solid tumors during these stages of progression, tumor B cells are also capable of inducing angiogenesis, both directly and indirectly by activating the inflammation infiltrate-a possibility that was first demonstrated by means of B-NHL implants onto the chick embryo chorioallantoic membrane. Anti-angiogenic therapy can be envisaged as a possible future development.

KW - Angiogenesis

KW - Multiple myeloma

KW - Non-Hodgkin's lymphoma

KW - S-phase cells

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=0029610669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029610669&partnerID=8YFLogxK

U2 - 10.3109/10428199509054750

DO - 10.3109/10428199509054750

M3 - Article

C2 - 8750620

AN - SCOPUS:0029610669

VL - 20

SP - 27

EP - 38

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -